ES2598961T3 - Derivados de ácido carbamoilmetoxiacético sustituido como inhibidores novedosos de NEP - Google Patents

Derivados de ácido carbamoilmetoxiacético sustituido como inhibidores novedosos de NEP Download PDF

Info

Publication number
ES2598961T3
ES2598961T3 ES14155848.6T ES14155848T ES2598961T3 ES 2598961 T3 ES2598961 T3 ES 2598961T3 ES 14155848 T ES14155848 T ES 14155848T ES 2598961 T3 ES2598961 T3 ES 2598961T3
Authority
ES
Spain
Prior art keywords
alkyl
ethylamino
tetrazol
biphenyl
ylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14155848.6T
Other languages
English (en)
Spanish (es)
Inventor
Yuki Iwaki
Toshio Kawanami
Gary Michael Ksander
Muneto Mogi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2598961T3 publication Critical patent/ES2598961T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
ES14155848.6T 2009-11-20 2010-11-18 Derivados de ácido carbamoilmetoxiacético sustituido como inhibidores novedosos de NEP Active ES2598961T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26313709P 2009-11-20 2009-11-20
US263137P 2009-11-20
US35991410P 2010-06-30 2010-06-30
US359914P 2010-06-30

Publications (1)

Publication Number Publication Date
ES2598961T3 true ES2598961T3 (es) 2017-01-30

Family

ID=43431937

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14155848.6T Active ES2598961T3 (es) 2009-11-20 2010-11-18 Derivados de ácido carbamoilmetoxiacético sustituido como inhibidores novedosos de NEP
ES10781884.1T Active ES2481890T3 (es) 2009-11-20 2010-11-18 Derivados de ácido carbamoilmetilamino acético sustituido como nuevos inhibidores de NEP

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10781884.1T Active ES2481890T3 (es) 2009-11-20 2010-11-18 Derivados de ácido carbamoilmetilamino acético sustituido como nuevos inhibidores de NEP

Country Status (37)

Country Link
US (4) US8222286B2 (cg-RX-API-DMAC10.html)
EP (2) EP2735561B1 (cg-RX-API-DMAC10.html)
JP (2) JP5543609B2 (cg-RX-API-DMAC10.html)
KR (1) KR101460421B1 (cg-RX-API-DMAC10.html)
CN (1) CN102666493B (cg-RX-API-DMAC10.html)
AR (1) AR079061A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010320930B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012011977A2 (cg-RX-API-DMAC10.html)
CA (1) CA2780150C (cg-RX-API-DMAC10.html)
CL (1) CL2012001298A1 (cg-RX-API-DMAC10.html)
CO (1) CO6540001A2 (cg-RX-API-DMAC10.html)
CR (1) CR20120237A (cg-RX-API-DMAC10.html)
DK (1) DK2501683T3 (cg-RX-API-DMAC10.html)
EA (1) EA021479B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP12011978A (cg-RX-API-DMAC10.html)
ES (2) ES2598961T3 (cg-RX-API-DMAC10.html)
GT (1) GT201200153A (cg-RX-API-DMAC10.html)
HN (1) HN2012001037A (cg-RX-API-DMAC10.html)
HR (1) HRP20140691T1 (cg-RX-API-DMAC10.html)
IL (1) IL219314A0 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN02465A (cg-RX-API-DMAC10.html)
JO (1) JO2967B1 (cg-RX-API-DMAC10.html)
MA (1) MA33886B1 (cg-RX-API-DMAC10.html)
MX (1) MX2012005813A (cg-RX-API-DMAC10.html)
MY (1) MY158299A (cg-RX-API-DMAC10.html)
NZ (1) NZ599136A (cg-RX-API-DMAC10.html)
PE (1) PE20121311A1 (cg-RX-API-DMAC10.html)
PH (1) PH12012500519A1 (cg-RX-API-DMAC10.html)
PL (1) PL2501683T3 (cg-RX-API-DMAC10.html)
PT (1) PT2501683E (cg-RX-API-DMAC10.html)
RS (1) RS53422B (cg-RX-API-DMAC10.html)
SI (1) SI2501683T1 (cg-RX-API-DMAC10.html)
TN (1) TN2012000125A1 (cg-RX-API-DMAC10.html)
TW (1) TWI481598B (cg-RX-API-DMAC10.html)
UY (1) UY33044A (cg-RX-API-DMAC10.html)
WO (1) WO2011061271A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201202018B (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
JO2967B1 (en) * 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
SG191175A1 (en) 2010-12-15 2013-07-31 Theravance Inc Neprilysin inhibitors
PH12013501240A1 (en) 2010-12-15 2015-09-16 Theravance Biopharma R & D Ip Llc Neprilysin inhibitors
WO2012112742A1 (en) 2011-02-17 2012-08-23 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
EP2675792B1 (en) 2011-02-17 2016-01-06 Theravance Biopharma R&D IP, LLC Substituted aminobutyric derivatives as neprilysin inhibitors
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
ES2653215T3 (es) 2011-05-31 2018-02-06 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
WO2012166390A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
EP2855464B1 (en) 2012-05-31 2016-10-26 Theravance Biopharma R&D IP, LLC Nitric oxide donor neprilysin inhibitors
CN104470521B (zh) 2012-06-08 2017-04-12 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
KR102102197B1 (ko) 2012-06-08 2020-04-20 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 억제제
NZ704741A (en) 2012-08-08 2017-10-27 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
KR20150119107A (ko) * 2013-02-14 2015-10-23 노파르티스 아게 개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체
CA2902456A1 (en) 2013-03-05 2014-09-12 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
EP3099668B1 (en) 2014-01-30 2022-05-04 Theravance Biopharma R&D IP, LLC 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
KR20160113291A (ko) 2014-01-30 2016-09-28 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프리리신 저해제
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
SG11201706308RA (en) 2015-02-11 2017-09-28 Theravance Biopharma R&D Ip Llc (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
CN107250119B (zh) 2015-02-19 2020-09-22 施万生物制药研发Ip有限责任公司 (2r,4r)-5-(5′-氯-2′-氟联苯-4-基)-2-羟基-4-[(5-甲基恶唑-2-羰基)氨基]戊酸
SMT202100434T1 (it) 2016-03-08 2021-09-14 Theravance Biopharma R&D Ip Llc Acido (2s,4r)-5-(5’-cloro-2-fluoro-[1,1’-bifenil]-4-il)-2-(etossimetil)-4-(3-idrossiisossazol-5-carbossammido)-2-metilpentanoico cristallino e suoi usi
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
CN113166204B (zh) 2018-11-27 2025-01-28 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
EP3986853A1 (en) 2019-06-19 2022-04-27 NMD Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188162C (nl) * 1978-11-25 1992-04-16 Nippon Kayaku Kk Werkwijze voor het bereiden van een bestatinederivaat.
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
IT1148006B (it) 1980-04-11 1986-11-26 Wellcome Found Ammidi dotate di proprieta' farmaceutiche e loro preparazione
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4610816A (en) * 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
IE53315B1 (en) * 1980-12-18 1988-10-12 Schering Corp Substituted dipeptides,processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase
US4721726A (en) * 1980-12-18 1988-01-26 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
JPS5865260A (ja) 1981-10-13 1983-04-18 Microbial Chem Res Found ３−アミノ−２−ヒドロキシ−４−フエニル酪酸誘導体および医薬組成物
FR2518088B1 (fr) 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
NZ201001A (en) * 1982-06-17 1986-02-21 Schering Corp Substituted dipeptide derivatives and method of preparation
EP0103077B1 (en) 1982-06-17 1988-05-18 Schering Corporation Substituted dipeptides, methods for their production, pharmaceutical compositions containing them, method for making such pharmaceutical compositions
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
AU569719B2 (en) 1983-01-28 1988-02-18 Schering Corporation Phosphorous compounds as inhibitors of enkephalinases
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
EP0136883B1 (en) 1983-10-03 1987-11-25 E.R. Squibb & Sons, Inc. Enkephalinase inhibitors
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS60248659A (ja) * 1984-05-25 1985-12-09 Microbial Chem Res Found ３−〔ｎ−（メルカプトアシル）〕アミノ−４−アリ−ル酪酸誘導体及びそれを有効成分とする鎮痛剤
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
FR2597865B1 (fr) 1986-04-29 1990-11-09 Roussel Uclaf Nouveaux derives d'un acide benzyl alkyl carboxylique substitue par un radical 4-pyridinyl aminocarbonyle, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
FR2605004B1 (fr) 1986-09-25 1989-01-13 Centre Nat Rech Scient Nouveaux derives d'amino-acides, leur procede de preparation et composition pharmaceutiques les contenant
CA1337400C (en) 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
FR2651229B1 (fr) 1989-08-24 1991-12-13 Inst Nat Sante Rech Med Nouveaux derives d'amino-acides, leur procede de preparation et leur application therapeutique.
FR2652087B1 (fr) * 1989-09-15 1993-10-15 Bioprojet Ste Civile Derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques.
AU7168091A (en) 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5223516A (en) * 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
US5200426A (en) * 1990-08-14 1993-04-06 Board Of Regents, The University Of Texas Inhibitors of neutral endopeptidase/CALLA as chemotherapeutic agents
JPH04149166A (ja) 1990-10-12 1992-05-22 Nippon Kayaku Co Ltd 新規ケト酸アミド誘導体
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
US5294632A (en) * 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE10075006I2 (de) 1991-06-21 2004-01-08 Boehringer Ingelheim Pharma Verwendung von (S)(+)-2-Äthoxy-4-[N-[1-(2-Piperidino-Phenyl)-3-Methyl-1-Butyl[Aminocarbonylmethyl]-Benzoesäure zur Herstellung eines Langzeitantidiabetikums.
GB9114006D0 (en) 1991-06-28 1991-08-14 Fujisawa Pharmaceutical Co New propionamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
DK0526171T3 (da) 1991-07-30 1997-08-25 Ajinomoto Kk Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf
EP0533130A1 (de) 1991-09-19 1993-03-24 Hoechst Aktiengesellschaft 2-Hydroxymethylpyridine, die entsprechenden Pyridin-N-oxide und ihre Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung
ZA927211B (en) 1991-09-27 1993-03-24 Merrell Dow Pharma Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE.
US5250522A (en) * 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5273990A (en) * 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
JPH06234630A (ja) 1992-12-17 1994-08-23 Tanabe Seiyaku Co Ltd 中性メタロエンドペプチダーゼ阻害剤
AU6267894A (en) 1993-03-02 1994-09-26 G.D. Searle & Co. N-acyl beta amino acid derivatives useful as platelet aggregation inhibitors
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5517996A (en) * 1994-04-21 1996-05-21 Hitachi Medical Corporation Ultrasonic diagnostic apparatus
IT1270261B (it) 1994-06-21 1997-04-29 Zambon Spa Derivati peptidici ad attivita' inibitrice delle metallopeptidasi
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5891912A (en) * 1994-11-04 1999-04-06 Santen Pharmaceutical Co., Ltd. 1,3-dialkylurea derivatives having a hydroxyl group
EP0798291B1 (en) * 1994-12-14 2002-09-11 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivatives
TW313568B (cg-RX-API-DMAC10.html) 1994-12-20 1997-08-21 Hoffmann La Roche
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US5710171A (en) * 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
IL118657A0 (en) 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
AU4159197A (en) 1996-09-04 1998-03-26 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
FR2755135B1 (fr) 1996-10-25 2002-12-27 Inst Nat Sante Rech Med Nouveaux derives d'(alpha-aminophosphino)peptides, leur procede de preparation et les compositions qui les contiennent
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
WO1998053817A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
WO1999026923A1 (en) 1997-11-20 1999-06-03 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en) 1997-11-21 1999-06-03 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
AU751950B2 (en) 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6169103B1 (en) * 1998-03-03 2001-01-02 Warner-Lambert Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP4070357B2 (ja) 1999-06-03 2008-04-02 花王株式会社 皮膚外用剤
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
US6677341B2 (en) 1999-09-23 2004-01-13 Pharmacia Corporation (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US6509330B2 (en) * 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
NZ521855A (en) 2000-04-12 2004-10-29 Novartis Ag Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a dirruretic to treat various conditions
ATE430567T1 (de) 2000-09-29 2009-05-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe zur behandlung von malaria
RU2334513C3 (ru) 2002-01-17 2017-10-24 Новартис Аг Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4233353B2 (ja) 2002-02-27 2009-03-04 田辺三菱製薬株式会社 医薬組成物
US20040063761A1 (en) * 2002-08-06 2004-04-01 Kuduk Scott D. 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives
ATE335744T1 (de) 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
AU2003292039A1 (en) 2002-11-18 2004-06-15 Novartis Ag Imidazo(1, 5a)pyridine derivatives and methods for treating aldosterone mediated diseases
US20040142379A1 (en) 2003-01-16 2004-07-22 Carlsberg Research Laboratory Affinity fishing for ligands and proteins receptors
CN1812979A (zh) 2003-04-30 2006-08-02 药物研发有限责任公司 作为蛋白酪氨酸磷酸酶－1b抑制剂的取代氨基羧酸
JP2007500707A (ja) 2003-07-29 2007-01-18 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリールヘテロ環状のアミン、アミドおよび硫黄−含有化合物、並びに該化合物の製造方法および使用方法
WO2005014532A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
ATE402180T1 (de) 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
BRPI0511621A (pt) 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
EP1749006A2 (en) 2004-05-28 2007-02-07 Speedel Experimenta AG Heterocyclic compounds and their use as aldosterone synthase inhibitors
US20080076794A1 (en) 2004-05-28 2008-03-27 Peter Herold Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
TW200611897A (en) 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
WO2006020358A2 (en) 2004-07-27 2006-02-23 Smithkline Beecham Corporation Novel biphenyl compounds and their use
WO2006015885A1 (en) 2004-08-13 2006-02-16 University College Dublin, National University Of Ireland, Dublin Amino acid dehydrogenase-derived biocatalysts
CA2588776A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids
WO2006069096A1 (en) 2004-12-20 2006-06-29 Pharmacyclics, Inc. Silanol derivatives as inhibitors of histone deacetylase
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2007045663A2 (en) 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2008122712A (ru) 2005-11-08 2009-12-20 Новартис АГ (CH) Комбинация органических соединений
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
CN101415803B (zh) 2006-04-04 2012-10-24 大阳日酸株式会社 甲烷分离方法、甲烷分离装置以及甲烷利用系统
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
CN101443007A (zh) 2006-05-15 2009-05-27 Irm责任有限公司 Terephthalamate化合物和组合物及其作为hiv整合酶抑制剂的用途
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CN101506216A (zh) 2006-08-25 2009-08-12 诺瓦提斯公司 用于治疗由醛固酮合酶和/或11-β-羟化酶和/或芳香酶介导的病症的稠合的咪唑衍生物
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
EP2094680A2 (en) 2006-12-18 2009-09-02 Novartis AG Imidazoles as aldosterone synthase inhibitors
JP2010513558A (ja) 2006-12-18 2010-04-30 ノバルティス アーゲー ４−イミダゾリル−１，２，３，４−テトラヒドロキノリン誘導体、およびアルドステロン／１１−ベータ−ヒドロキシラーゼ阻害剤としてのその使用
KR20090094374A (ko) 2006-12-18 2009-09-04 노파르티스 아게 1-치환된 이미다졸 유도체 및 알도스테론 신타제 억제제로서의 그의 용도
NZ577910A (en) 2007-01-12 2012-04-27 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
MX2009008264A (es) 2007-03-29 2009-08-12 Novartis Ag Compuestos espiro heterociclicos.
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
US8980833B2 (en) 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP3067043B1 (en) 2007-11-06 2022-11-30 Novartis AG Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
CA2705921A1 (en) 2007-12-11 2009-06-18 Theravance, Inc. Dual-acting benzoimidazole derivatives and their use as antihypertensive agents
EP2070928A1 (en) 2007-12-12 2009-06-17 NERVIANO MEDICAL SCIENCES S.r.l. 7-azaindol-3-ylacrylamides active as kinase inhibitors
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
MX2011012627A (es) * 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
CA2772681C (en) 2009-09-23 2017-01-03 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Process for manufacture of n-acylbphenyl alanine
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors

Also Published As

Publication number Publication date
CN102666493A (zh) 2012-09-12
PL2501683T3 (pl) 2014-09-30
EP2501683B1 (en) 2014-04-23
US20110124695A1 (en) 2011-05-26
ES2481890T3 (es) 2014-07-31
ECSP12011978A (es) 2012-07-31
TWI481598B (zh) 2015-04-21
IL219314A0 (en) 2012-06-28
DK2501683T3 (da) 2014-06-30
TN2012000125A1 (en) 2013-09-19
JO2967B1 (en) 2016-03-15
US20130096168A1 (en) 2013-04-18
US20120202862A1 (en) 2012-08-09
PE20121311A1 (es) 2012-10-12
NZ599136A (en) 2013-07-26
AU2010320930A1 (en) 2012-04-12
KR20120084327A (ko) 2012-07-27
US8222286B2 (en) 2012-07-17
PH12012500519A1 (en) 2012-10-22
MY158299A (en) 2016-09-30
EP2735561A1 (en) 2014-05-28
HN2012001037A (es) 2015-08-10
UY33044A (es) 2011-06-30
JP5543609B2 (ja) 2014-07-09
JP2014167015A (ja) 2014-09-11
CL2012001298A1 (es) 2012-10-05
SI2501683T1 (sl) 2014-07-31
CR20120237A (es) 2012-06-07
CA2780150C (en) 2017-10-17
ZA201202018B (en) 2012-11-28
EA201200763A1 (ru) 2012-12-28
MA33886B1 (fr) 2013-01-02
RS53422B (sr) 2014-12-31
US20140088165A1 (en) 2014-03-27
MX2012005813A (es) 2012-06-12
HRP20140691T1 (hr) 2014-10-24
CA2780150A1 (en) 2011-05-26
EP2735561B1 (en) 2016-07-20
KR101460421B1 (ko) 2014-11-10
US8377978B2 (en) 2013-02-19
IN2012DN02465A (cg-RX-API-DMAC10.html) 2015-08-21
US8877786B2 (en) 2014-11-04
HK1170475A1 (en) 2013-03-01
AR079061A1 (es) 2011-12-21
WO2011061271A1 (en) 2011-05-26
JP2013510835A (ja) 2013-03-28
EP2501683A1 (en) 2012-09-26
TW201121949A (en) 2011-07-01
BR112012011977A2 (pt) 2020-09-08
CN102666493B (zh) 2015-09-23
PT2501683E (pt) 2014-07-24
GT201200153A (es) 2014-12-30
EA021479B1 (ru) 2015-06-30
US8642635B2 (en) 2014-02-04
AU2010320930B2 (en) 2014-05-15
CO6540001A2 (es) 2012-10-16

Similar Documents

Publication Publication Date Title
ES2598961T3 (es) Derivados de ácido carbamoilmetoxiacético sustituido como inhibidores novedosos de NEP
ES2587447T3 (es) Método de tratamiento de nefropatía inducida por medio de contraste
ES2550479T3 (es) Derivados de heteroarilo bicíclico condensado
ES2653205T3 (es) Procedimiento de preparación de derivados de diamida del ácido antranílico sustituidos con tetrazol mediante la reacción de ácidos de pirazol con ésteres del ácido antranílico
ES2508765T3 (es) Procedimiento para producir un compuesto de 5-hidroxi-4-tiometilpirazol
US8211914B2 (en) Inhibitors of diacylglycerol acyltransferase
ES2321535T3 (es) Compuestos de piridina para el tratamiento de enfermedades mediadas por prostaglandinas.
BR112015002779A2 (pt) processo para a preparação de derivados de ácido carboxílico de pirazol
AU2007238879A1 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
ES2365011T3 (es) Nuevas moléculas bioactivas.
CN101641363A (zh) 含磷的α-酮酸的制造方法
US11434238B2 (en) Method for producing triazolopyridine compound
US20070281969A1 (en) Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
CN102295655A (zh) 一种氧头孢烯类抗菌素中间体溶剂化物及其制备方法
ES2204302B2 (es) Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
EP2025665B1 (en) Process for producing substituted aniline compound
WO2007035478A2 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
US20070088159A1 (en) Hydroxyalkyl cyclic diamine compounds
US9388172B2 (en) Substituted carbamate compounds
TW312691B (cg-RX-API-DMAC10.html)
ES2352819T3 (es) Procedimiento para la producción de un compuesto de anilina sustituido.
JP4983112B2 (ja) ３−（ヒドロキシ又はアルコキシ）−４−アルコキシ−６−ニトロ安息香酸化合物の製法
JP3044383B2 (ja) 含窒素６員環化合物の製造方法
RU2649006C2 (ru) Способ синтеза гидразина, который можно применять при лечении вируса папилломы
JP2519178B2 (ja) ５−（４−ピリジル）オキサゾ―ルの製造法